Beyond The Numbers: 4 Analysts Discuss Gritstone Bio Stock
Portfolio Pulse from Benzinga Insights
Gritstone Bio (NASDAQ:GRTS) received mixed analyst ratings, with a recent shift towards more bullish perspectives. The average 12-month price target is now $5.00, down 9.09% from the previous target. Financial challenges include a significant revenue decline and poor profitability metrics. Analysts' actions and price target adjustments reflect dynamic market conditions and company performance.

May 13, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gritstone Bio received mixed analyst ratings, with a downward adjustment in the average price target to $5.00. The company faces significant financial challenges, including a drastic revenue decline and poor profitability metrics.
The mixed analyst ratings, combined with a significant decrease in the average price target, suggest a cautious or negative outlook for GRTS in the short term. The financial challenges, including a severe revenue decline and poor profitability metrics, further support a negative impact on the stock price. The adjustments in analyst ratings and price targets reflect concerns about the company's current financial health and future prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100